Targeted-Release Formulation Budesonide (Nefecon) for the Treatment of IgA Nephropathy in Three Adolescents.

Authors

Tong Yiming, Zhu Xinyi, Ouyang Yan, Xu Jing, Hu Xiaofan, Pan Xiaoxia, Yin Lei, Xie Jingyuan

Published in

Kidney360. Oct 08, 2026. Epub Oct 08, 2026.

Abstract

IgA nephropathy (IgAN) is the most prevalent primary glomerular disease in adolescents, with 20% progressing to end-stage kidney disease within 20 years[1]. Targeted-release formulation (TRF) budesonide (Nefecon-IgAN-specific TRF-budesonide) is FDA-approved for adult IgAN but lacks evidence in adolescents[2]. We describe three adolescents with biopsy-proven IgAN treated with 16 mg/d Nefecon for 9-12 months (one patient with extension). All showed marked reductions in proteinuria and hematuria with stable renal function. No serious AEs were reported. These cases provide preliminary clinical experience regarding the feasibility and tolerability of Nefecon in selected adolescents with IgAN.

PMID:
42848663
Bibliographic data and abstract were imported from PubMed on 09 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.